Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $11.6B | $11.0B | $9.9B | $9.3B | $9.9B | $10.8B | $9.4B | $7.7B | $7.5B | $7.7B | $7.5B | $7.5B | $7.4B | $7.1B | $7.4B | $7.5B | $7.4B | $7.5B | $7.2B | $6.7B | $6.3B |
| Bruttoergebnis | $3.8B | $3.5B | $3.2B | $3.1B | $3.4B | $4.2B | $3.6B | $2.7B | $2.6B | $3.0B | $2.9B | $2.8B | $2.8B | $2.8B | $3.0B | $3.1B | $3.1B | $3.1B | $3.0B | $2.7B | $2.6B |
| Bruttomarge % | 33.1% | 31.9% | 32.9% | 33.0% | 34.7% | 39.0% | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | 39.5% | 40.9% | 41.5% | 41.4% | 42.0% | 41.3% | 40.8% | 41.0% |
| Betriebsergebnis (EBIT) | $1.6B | $1.6B | $1.3B | $1.3B | $1.4B | $2.4B | $2.0B | $1.2B | $1.1B | $1.2B | $1.3B | $1.4B | $983M | $1.5B | $1.2B | $995M | $1.3B | $1.4B | $1.2B | $1.1B | $1.1B |
| Operative Marge % | 14.1% | 14.5% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | 20.6% | 16.3% | 13.2% | 17.6% | 18.2% | 16.9% | 16.3% | 18.0% |
| Jahresüberschuss | $1.1B | $992M | $871M | $854M | $946M | $2.0B | $1.4B | $858M | $736M | $772M | $645M | $709M | $556M | $849M | $556M | $471M | $721M | $729M | $582M | $340M | $586M |
| Nettomarge % | 9.2% | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | 11.9% | 7.5% | 6.3% | 9.8% | 9.8% | 8.0% | 5.1% | 9.3% |
| EBITDA | — | $2.2B | $1.9B | $1.3B | $1.8B | $3.2B | $2.4B | $1.6B | $1.4B | $1.5B | $1.5B | $1.6B | $1.3B | $1.8B | $1.5B | $1.3B | $1.6B | $1.6B | $1.5B | $1.3B | $1.3B |
| Ergebnis je Aktie (EPS) | $9.45 | $8.78 | $7.71 | $7.56 | $8.02 | $15.59 | $10.52 | $6.31 | $5.29 | $5.51 | $4.54 | $4.89 | $3.83 | $5.55 | $3.47 | $2.94 | $4.07 | $3.88 | $2.97 | $1.74 | $2.94 |
| Ausstehende Aktien (Mio.) | — | 113M | 113M | 113M | 118M | 128M | 136M | 136M | 139M | 140M | 142M | 145M | 145M | 153M | 160M | 160M | 177M | 188M | 196M | 195M | 200M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für DGX. /companies/us/DGX
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms